Pew on Biotech? Pugh!

Image: Anthony Canamucio Controversies--or perhaps pseudocontroversies would be more apt--continue to engulf recombinant DNA technology, the "new biotechnology," applied to agriculture and food production. One theoretical concern is that consumers might experience allergic reactions to foods made from recombinant organisms. In a June 2002 report, the Pew Initiative on Food and Biotechnology concluded that regulatory agencies might have difficulty evaluating the potential for allergic reactions

Written byHenry Miller
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

Controversies--or perhaps pseudocontroversies would be more apt--continue to engulf recombinant DNA technology, the "new biotechnology," applied to agriculture and food production. One theoretical concern is that consumers might experience allergic reactions to foods made from recombinant organisms. In a June 2002 report, the Pew Initiative on Food and Biotechnology concluded that regulatory agencies might have difficulty evaluating the potential for allergic reactions caused by foods from the next generation of recombinant DNA-modified organisms.1

This report has garnered attention from government agencies and the mainstream press, largely because the Pew Initiative touts itself as occupying the thoughtful middle ground in the biotechnology debates. Pew's PR machine makes this claim, but that doesn't make it so, and it isn't.

The Pew Initiative is different from other antibiotech players that show their colors unambiguously--like political activist Jeremy Rifkin, who has characterized biotechnology as threatening "a form of annihilation every bit as deadly as ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies